AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01123265
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will start Methotrexate which will be escalated from 7.5 mg weekly to 15 mg/weekly over a 3 week period.
Trial: NCT01123265
Drug: Anti-TNF
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF to be administered per standard of care within the practice.
Trial: NCT01250340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cp day for 30 days
Trial: NCT04521023
Drug: Cantabell Tab
RxNorm normalized name: ZINC OXIDE 200 mg in 1 mL TOPICAL LOTION [CannaCell Sun Buddy Facial SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to experimental group are treated with Cantabell Tab
Trial: NCT00318461
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride placebo 1 mg and 2 mg tablets
Trial: NCT00318461
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide placebo 1-3 mL for s.c. (under the skin) injection
Trial: NCT04772105
Drug: 2.5mg of BAT5906
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification: 2.5mg of BAT5906
Trial: NCT04772105
Drug: 4.0mg of BAT5906
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification: 4.0mg of BAT5906
Trial: NCT00617305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match ambrisentan was administered orally once daily.
Trial: NCT04207801
Drug: AUR101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitor of RORγ
Trial: NCT04207801
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Placebo of AUR101 tablet
Trial: NCT02615847
Drug: Memantinhydrochlorid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantin Mepha® Lactabs (memantinehydrochlorid) will be provided as 5 mg, 10 mg, 15 mg and 20 mg tablets, packed in blister.~The study drug will be taken once a day per os, during 12 month.
Trial: NCT00715702
Drug: AZD5672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral single dose
Trial: NCT03484091
Drug: Hyruan-One
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose intra-articular injection
Trial: NCT03484091
Drug: Hylan G-F 20
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose intra-articular injection
Trial: NCT03484091
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose intra-articular injection
Trial: NCT00115726
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will be given placebo capsules (identical to experimental arm in color) at the equivalent dose as to their chronic furosemide therapy.
Trial: NCT02735122
Drug: acetaminophen Tablet
RxNorm normalized name: Acetaminophen Tablets
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 test acetaminophen 500 mg tablets
Trial: NCT02735122
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo tablets
Trial: NCT02735122
Drug: Placebo Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo caplets
Trial: NCT02735122
Drug: Placebo Liquid-filled capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo Liquid-filled capsules
Trial: NCT00096798
Drug: Ethyl-eicosapentanoic acid (ethyl-EPA)
RxNorm normalized name: Eicosapentaenoic acid ethyl ester
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02785003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
Trial: NCT02785003
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance \< 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
Trial: NCT02785003
Drug: Opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment.
Trial: NCT02305095
Drug: FDC I/H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects in both groups will be initiated on drug, FDC I/H with dose titrated up to target doses based on clinical guidelines
Trial: NCT02833389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UTTR1147A matching placebo will be administered SC.
Trial: NCT02833389
Drug: UTTR1147A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UTTR1147A will be administered SC.
Trial: NCT01537861
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01940471
Drug: TAF
RxNorm normalized name: Altafed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg tablet administered orally once daily
Trial: NCT01940471
Drug: TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT01532141
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg BIA 9-1067 (single-dose)
Trial: NCT01940471
Drug: TDF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT00864097
Drug: diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral diclofenac SR 75 mg BID for 32 weeks
Trial: NCT01622504
Drug: MVP005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg single dose administered intranasally
Trial: NCT03368118
Drug: ABX464
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive ABX464 given at 50 mg o.d for an overall period of 48 months.
Trial: NCT00698230
Drug: INCB013739
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB013739 5 mg QD tablet
Trial: NCT00698230
Drug: INCB013739
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB013739 15 mg QD tablet
Trial: NCT00698230
Drug: INCB013739
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB013739 50 mg QD tablet
Trial: NCT00698230
Drug: INCB013739
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB013739 100 mg QD tablet
Trial: NCT00698230
Drug: INCB013739
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB013739 200 mg QD
Trial: NCT00698230
Drug: Placebo comparator matching INCB013739
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally once daily tablet
Trial: NCT01622504
Drug: MVP005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg single dose administered intranasally
Trial: NCT01033565
Drug: Natrol
RxNorm normalized name: Natrol SAMe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg of sustained released melatonin. One tablet given 30 minutes prior to bedtime.
Trial: NCT02803528
Drug: Biodentine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biodentine is going to be used as the direct pulp capping material
Trial: NCT01003002
Drug: Levodopa (delivered intravenously)
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One mg/kg/hr of Levodopa will be given intravenously during inpatient testing days from 0900 to 1100.
Trial: NCT02048618
Drug: GLPG0634
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral tablet, intake once daily for 20 weeks
Trial: NCT02048618
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral tablets, intake once daily for 20 weeks
Trial: NCT01998217
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in Rem group receive sedation and analgesia with remifentanil, dose of which will be determined by the up-and-down method.
Trial: NCT01998217
Drug: Flurbiprofen and remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group receive sedation and analgesia with flurbiprofen and remifentanil, dose of which was determined by the up-and-down method.
Trial: NCT00815763
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion placebo once a day and continued for 14 day
Trial: NCT03858036
Drug: Ricrolin+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 2 drops of Ricrolin+ will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the Ricrolin+ pre-treatment period, the eye will be examined at the slit lamp to detect the presence of a yellow flare in the anterior chamber, indicating adequate riboflavin saturation of the corneal tissue. If the yellow flare is not detected, Ricrolin+ will continue to be instilled 1 drop every 2 minutes for an additional 5 to 10 minutes; and the anterior chamber will be rechecked for yellow flare. This process will be repeated as necessary. During the irradiation period, 1 to 2 drops of Ricrolin+ to cover the cornea (in the same manner as during the riboflavin pre-treatment) before the start of irradiation and every 5 minutes during irradiation until irradiation is complete.
Trial: NCT02158182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (for lactulose) 30ml of dextrose solution by mouth three times daily, for 7 days.~Placebo (for L-ornithine L-aspartate) saline solution 500ml by intravenous way for 24 hours, for 7 days.~Placebo (for rifaximin) 2 dextrose tablets three times daily for 7 days.
Trial: NCT02006160
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bid
Trial: NCT01219322
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous normal saline volume equivalent to sodium bicarbonate
Trial: NCT01413581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to infant formula/pasteurized breast milk during a 4 week treatment period.
Trial: NCT03447262
Drug: VX-659/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablets for oral administration qd in the morning.
Trial: NCT02548403
Drug: PEG-Asc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
Trial: NCT02841098
Drug: Optimal medical therapy alone
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy alone
Trial: NCT02680132
Drug: Nexium 40 mg DR Capsules of AstraZeneca LP, USA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, cross over
Trial: NCT00317720
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 10 mg by mouth daily. Phase I dose finding from two dose levels of daily RAD001 (5 and 10 mg).
Trial: NCT04349592
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 250 mg capsules oral, 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
Trial: NCT01758627
Drug: Peritoneal dialysis (PD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD exchanges will be customized depending on patient fluid status. At least one daily exchange of icodextrin PD solution will be provided to PD group.
Trial: NCT00318214
Drug: MRE0094
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel, 500 mcg/g once each day
Trial: NCT00318214
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel administered once per day
Trial: NCT01395875
Drug: Anticholinergics (AC)
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPD patients receiving anticholinergics (ACs) including tiotropium (TIO) and ipratropium or combination ipratropium-albuterol (collectively referred to as ipratropium \[IPR\]).
Trial: NCT01788033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg Placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
Trial: NCT00281645
Drug: Standard of Care (pharmacological analgesic treatment)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03163589
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection
Trial: NCT01414972
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cap placebo/day for 3 month
Trial: NCT03636763
Drug: data report
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the information gliptin exposure will be reported
Trial: NCT00524264
Drug: ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.~Placebo
Trial: NCT01342484
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different dosages of drug (low vs high) vs placebo
Trial: NCT00126191
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low Risk/High Risk: Intravenously on day 1 and day 2 of a 14-day cycle for 3 cycles (regimen A)
Trial: NCT00126191
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low Risk/High Risk: Given on day 1 of a 14-day cycle for 3 cycles (regimen A)
Trial: NCT00126191
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low Risk: Given on day 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: Regimen A followed by methotrexate on day 3 and day 5 of a 5-day cycle
Trial: NCT01292720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in matching volumes
Trial: NCT00126191
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low Risk/High Risk: Given on days 11, 12 and 13 of a 14-day cycle for 3 cycles (regimen A)
Trial: NCT00617877
Drug: Comparator: Hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
Trial: NCT03143803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar looking inactive powder
Trial: NCT02431416
Drug: Gonadotropin releasing hormone (GnRH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin releasing hormone GnRH (Relefact LHRH) iv injection, single dose, 100 micrograms/square meter body surface, maximum dose: 100 microgram.
Trial: NCT02603770
Drug: XueZhiKang
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02603770
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02164929
Drug: Acetaminophen 1g IV
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02164929
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1:200,000 epinephrine
Trial: NCT00385593
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00304083
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00532090
Drug: RG4733
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally daily at ascending doses to successive cohorts of patients
Trial: NCT00532090
Drug: RG4733
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally at ascending doses to successive cohorts of patients, on a 3 days on/ 4 days off schedule
Trial: NCT00532090
Drug: RG4733
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally at ascending doses to successive cohorts of patients, on days 1-7 of each 21 day cycle
Trial: NCT04351555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02456935
Drug: CJ-12420 100 mg QD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100 mg.
Trial: NCT00227136
Drug: 5-Hydroxy-Tryptamine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03543189
Drug: Androgen Deprivation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care.
Trial: NCT00781586
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine 100 mg 1 tablet at 1st visit
Trial: NCT00781586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 tablet at 1st visit
Trial: NCT01165905
Drug: ON 01910.Na
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose of ON 01910.Na is 250 mg/m2 as a 24 hour intravenous (i.v.) infusion on days 1, 8 and 15 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 250 mg/m2, DL 2 = 650 mg/m2, DL 3 = 1050 mg/m2, DL 4= 1350 mg/m2) of new patients. A course is defined as 4 weeks in length.
Trial: NCT01970215
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01970215
Drug: Placebo Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00999791
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03938246
Drug: TVB-2640 50 mg (US)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose, tablet, daily dosing
Trial: NCT03938246
Drug: Placebo (US)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose, tablet, daily dosing
Trial: NCT00415363
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, daily
Trial: NCT03061734
Drug: Naltrexone and Acetaminophen
RxNorm normalized name: bupropion and naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone plus acetaminophen
Trial: NCT03061734
Drug: Naltrexone and Acetaminophen-High Dose
RxNorm normalized name: bupropion and naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexon (high dose) plus acetaminophen
Trial: NCT03938246
Drug: TVB-2640 75 mg (US)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose, tablet, daily dosing
Trial: NCT03061734
Drug: Acetaminophen Alone
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen Alone plus Placebo
Trial: NCT03061734
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two Placebo capsules
Trial: NCT02134834
Drug: OP0595
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
Trial: NCT02134834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
Trial: NCT00631020
Drug: Optional NRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NicoDerm CQ nicotine transdermal patch
Trial: NCT03295877
Drug: RO7171009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive RO7171009 via ITV injection.
Trial: NCT00068744
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01179464
Drug: Aminobiphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive standard intravenous biphosphonate treatment
Trial: NCT01179464
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg once daily
Trial: NCT02243254
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous ibuprofen
Trial: NCT02053116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 0 mg, twice daily, 2 weeks
Trial: NCT02197247
Drug: AZD9291 tablet dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: AZD9291 80mg tablet taken daily from Days 1 to 77. Part B: AZD9291 80mg tablet taken daily for 12 months.
Trial: NCT01821612
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT01821612
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO